Why investors just bet $85M on this Indian company’s generic drug strategy

In a significant move for the healthcare sector, Truemeds, a Mumbai-based startup, has successfully raised $85 million in a recent funding round, boosting its valuation to over $400 million. This funding, which includes $65 million in primary investments and $20 million from secondary sources, was led by Accel and saw participation from Peak XV Partners, as well as existing investors WestBridge Capital and InfoEdge Ventures. Truemeds has carved out a unique niche in India’s competitive online pharmacy landscape, focusing on promoting affordable generic medications. With around 400 million chronic patients in India, the demand for cost-effective healthcare solutions is immense. Unlike many e-pharmacies that prioritize speed, Truemeds emphasizes the importance of affordability, helping patients transition to lower-cost alternatives. Founded in 2019, Truemeds launched into a market already populated with major players offering substantial discounts on branded generics. While others like PharmEasy have faced declining valuations, Truemeds has witnessed remarkable growth, with revenue surging over 66% year-over-year to reach ₹5 billion (approximately $57 million) in the last financial year. The company serves an impressive 500,000 customers monthly, with a total user base of 3 million, primarily from tier-2 cities across India. Despite its success, Truemeds faces the ongoing challenge of educating consumers about the benefits of switching from prescribed branded medications to generics. Co-founder Akshat Nayyar highlighted the importance of addressing consumer concerns, stating that many patients are hesitant to choose lower-priced options without understanding the reasons behind the price difference. Truemeds’ strategy includes offering higher average discounts—now at 32%—and leveraging strong procurement relationships with pharmaceutical manufacturers to enhance demand visibility. This approach not only aids in efficient production planning but also enables Truemeds to pass savings directly to consumers. Nayyar noted that the startup provides an average savings of 47% for users who switch brands through its platform. In addition to its focus on affordability, Truemeds is also developing advanced technologies to improve customer interactions. The startup plans to implement an AI-driven system for personalized customer communication, ensuring tailored suggestions for generic alternatives. Furthermore, Truemeds aims to expand its services beyond pharmaceuticals by partnering with national pathology labs to introduce diagnostic testing in various tier-2 cities within the next few months. With plans to increase its fulfillment centers by 300% and enhance its engineering and product development efforts, Truemeds is poised to solidify its position as a leader in affordable healthcare solutions in India. The company remains committed to its mission of making healthcare accessible and affordable for all, starting with medications and extending into diagnostics.